Startup profile · funding coverage
Cleveland Diagnostics funding, valuation and investors
Cancer diagnostics company commercializing IsoPSA and the IsoClear protein-structure platform.
Keep track of Cleveland Diagnostics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Cleveland, OH
Overview
Cleveland Diagnostics develops blood tests using its IsoClear platform that analyzes protein structural differences linked to cancer biology. First commercial test IsoPSA targets prostate cancer risk stratification. Headquarters: 3615 Superior Avenue, Cleveland, OH 44114. Formerly AnalizaDx; founded ~2017 per CB Insights-class profiles.
Why Cleveland Diagnostics is interesting
Cleveland Clinic–adjacent diagnostics builder HQ’d on Superior Avenue — IsoPSA aims to reduce unnecessary prostate biopsies.
Product & use cases
Blood-based cancer diagnostic tests; IsoPSA for clarifying high-grade prostate cancer risk.
- Urology biopsy decision support
- Cancer diagnostic workups
Key facts
- HQ: 3615 Superior Avenue, Cleveland, OH
- Product: IsoPSA prostate cancer test
- Platform: IsoClear protein structure analysis
- Clinical literature cited on company site for biopsy reduction claims
Competitive landscape
Edge: Protein-structure approach vs concentration-only PSA paradigms.
-
OPKO 4Kscore / SelectMDx direct
Prostate risk tests.
-
Exact Sciences / other cancer dx adjacent
Broader cancer diagnostics.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Cleveland Diagnostics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.